Literature DB >> 19020025

Crucial role of alpha4 and alpha6 nicotinic acetylcholine receptor subunits from ventral tegmental area in systemic nicotine self-administration.

S Pons1, L Fattore, G Cossu, S Tolu, E Porcu, J M McIntosh, J P Changeux, U Maskos, W Fratta.   

Abstract

The identification of the molecular mechanisms involved in nicotine addiction and its cognitive consequences is a worldwide priority for public health. Novel in vivo paradigms were developed to match this aim. Although the beta2 subunit of the neuronal nicotinic acetylcholine receptor (nAChR) has been shown to play a crucial role in mediating the reinforcement properties of nicotine, little is known about the contribution of the different alpha subunit partners of beta2 (i.e., alpha4 and alpha6), the homo-pentameric alpha7, and the brain areas other than the ventral tegmental area (VTA) involved in nicotine reinforcement. In this study, nicotine (8.7-52.6 microg free base/kg/inf) self-administration was investigated with drug-naive mice deleted (KO) for the beta2, alpha4, alpha6 and alpha7 subunit genes, their wild-type (WT) controls, and KO mice in which the corresponding nAChR subunit was selectively re-expressed using a lentiviral vector (VEC mice). We show that WT mice, beta2-VEC mice with the beta2 subunit re-expressed exclusively in the VTA, alpha4-VEC mice with selective alpha4 re-expression in the VTA, alpha6-VEC mice with selective alpha6 re-expression in the VTA, and alpha7-KO mice promptly self-administer nicotine intravenously, whereas beta2-KO, beta2-VEC in the substantia nigra, alpha4-KO and alpha6-KO mice do not respond to nicotine. We thus define the necessary and sufficient role of alpha4beta2- and alpha6beta2-subunit containing nicotinic receptors (alpha4beta2*- and alpha6beta2*-nAChRs), but not alpha7*-nAChRs, present in cell bodies of the VTA, and their axons, for systemic nicotine reinforcement in drug-naive mice.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19020025      PMCID: PMC2819191          DOI: 10.1523/JNEUROSCI.3918-08.2008

Source DB:  PubMed          Journal:  J Neurosci        ISSN: 0270-6474            Impact factor:   6.167


  78 in total

1.  Self-administration of the cannabinoid receptor agonist WIN 55,212-2 in drug-naive mice.

Authors:  M C Martellotta; G Cossu; L Fattore; G L Gessa; W Fratta
Journal:  Neuroscience       Date:  1998-07       Impact factor: 3.590

2.  Acetylcholine receptors containing the beta2 subunit are involved in the reinforcing properties of nicotine.

Authors:  M R Picciotto; M Zoli; R Rimondini; C Léna; L M Marubio; E M Pich; K Fuxe; J P Changeux
Journal:  Nature       Date:  1998-01-08       Impact factor: 49.962

3.  Gamma-hydroxybutyric acid decreases intravenous cocaine self-administration in rats.

Authors:  M C Martellotta; C Balducci; L Fattore; G Cossu; G L Gessa; L Pulvirenti; W Fratta
Journal:  Pharmacol Biochem Behav       Date:  1998-03       Impact factor: 3.533

4.  Nicotine activation of alpha4* receptors: sufficient for reward, tolerance, and sensitization.

Authors:  Andrew R Tapper; Sheri L McKinney; Raad Nashmi; Johannes Schwarz; Purnima Deshpande; Cesar Labarca; Paul Whiteaker; Michael J Marks; Allan C Collins; Henry A Lester
Journal:  Science       Date:  2004-11-05       Impact factor: 47.728

5.  Nicotine-induced decreases in VTA electrical self-stimulation thresholds: blockade by haloperidol and mecamylamine but not scopolamine or ondansetron.

Authors:  S Ivanová; A J Greenshaw
Journal:  Psychopharmacology (Berl)       Date:  1997-11       Impact factor: 4.530

6.  Discrimination and self-administration of nicotine by inbred strains of mice.

Authors:  I P Stolerman; C Naylor; G I Elmer; S R Goldberg
Journal:  Psychopharmacology (Berl)       Date:  1999-01       Impact factor: 4.530

7.  Unresponsiveness to cannabinoids and reduced addictive effects of opiates in CB1 receptor knockout mice.

Authors:  C Ledent; O Valverde; G Cossu; F Petitet; J F Aubert; F Beslot; G A Böhme; A Imperato; T Pedrazzini; B P Roques; G Vassart; W Fratta; M Parmentier
Journal:  Science       Date:  1999-01-15       Impact factor: 47.728

8.  Identification of four classes of brain nicotinic receptors using beta2 mutant mice.

Authors:  M Zoli; C Léna; M R Picciotto; J P Changeux
Journal:  J Neurosci       Date:  1998-06-15       Impact factor: 6.167

9.  Intravenous self-administration of gamma-hydroxybutyric acid in drug-naive mice.

Authors:  M C Martellotta; G Cossu; L Fattore; G L Gessa; W Fratta
Journal:  Eur Neuropsychopharmacol       Date:  1998-12       Impact factor: 4.600

10.  Reinforcing effects of nicotinic compounds: intravenous self-administration in drug-naive mice.

Authors:  T Rasmussen; M D Swedberg
Journal:  Pharmacol Biochem Behav       Date:  1998-06       Impact factor: 3.533

View more
  189 in total

Review 1.  The use of α-2A adrenergic agonists for the treatment of attention-deficit/hyperactivity disorder.

Authors:  Amy F T Arnsten
Journal:  Expert Rev Neurother       Date:  2010-10       Impact factor: 4.618

2.  Effects of sazetidine-A, a selective alpha4beta2 nicotinic acetylcholine receptor desensitizing agent on alcohol and nicotine self-administration in selectively bred alcohol-preferring (P) rats.

Authors:  Amir H Rezvani; Susan Slade; Cori Wells; Ann Petro; Lawrence Lumeng; Ting-Kai Li; Yingxian Xiao; Milton L Brown; Mikell A Paige; Brian E McDowell; Jed E Rose; Kenneth J Kellar; Edward D Levin
Journal:  Psychopharmacology (Berl)       Date:  2010-06-10       Impact factor: 4.530

3.  Nicotinic cholinergic mechanisms causing elevated dopamine release and abnormal locomotor behavior.

Authors:  B N Cohen; E D W Mackey; S R Grady; S McKinney; N E Patzlaff; C R Wageman; J M McIntosh; M J Marks; H A Lester; R M Drenan
Journal:  Neuroscience       Date:  2011-11-04       Impact factor: 3.590

Review 4.  Positive and negative effects of alcohol and nicotine and their interactions: a mechanistic review.

Authors:  Laura L Hurley; Robert E Taylor; Yousef Tizabi
Journal:  Neurotox Res       Date:  2011-09-20       Impact factor: 3.911

5.  Modulation of gain-of-function α6*-nicotinic acetylcholine receptor by β3 subunits.

Authors:  Bhagirathi Dash; Ronald J Lukas
Journal:  J Biol Chem       Date:  2012-02-07       Impact factor: 5.157

6.  AT-1001: a high affinity and selective α3β4 nicotinic acetylcholine receptor antagonist blocks nicotine self-administration in rats.

Authors:  Lawrence Toll; Nurulain T Zaveri; Willma E Polgar; Faming Jiang; Taline V Khroyan; Wei Zhou; Xinmin Simon Xie; Gregory B Stauber; Matthew R Costello; Frances M Leslie
Journal:  Neuropsychopharmacology       Date:  2012-01-25       Impact factor: 7.853

7.  Pharmacogenetics of smoking cessation: role of nicotine target and metabolism genes.

Authors:  Allison B Gold; Caryn Lerman
Journal:  Hum Genet       Date:  2012-01-31       Impact factor: 4.132

Review 8.  Neuropharmacology of the interoceptive stimulus properties of nicotine.

Authors:  Thomas E Wooters; Rick A Bevins; Michael T Bardo
Journal:  Curr Drug Abuse Rev       Date:  2009-09

9.  Structural differences determine the relative selectivity of nicotinic compounds for native alpha 4 beta 2*-, alpha 6 beta 2*-, alpha 3 beta 4*- and alpha 7-nicotine acetylcholine receptors.

Authors:  Sharon R Grady; Ryan M Drenan; Scott R Breining; Daniel Yohannes; Charles R Wageman; Nikolai B Fedorov; Sheri McKinney; Paul Whiteaker; Merouane Bencherif; Henry A Lester; Michael J Marks
Journal:  Neuropharmacology       Date:  2010-01-28       Impact factor: 5.250

Review 10.  From smoking to lung cancer: the CHRNA5/A3/B4 connection.

Authors:  M R D Improgo; M D Scofield; A R Tapper; P D Gardner
Journal:  Oncogene       Date:  2010-06-28       Impact factor: 9.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.